Learn more about the benefits and risks of taking Lovenox during pregnancy. While most pregnancies progress smoothly and without serious medical issues, pregnancy usually doesn’t come without some ...

Lovenox (enoxaparin) is a prescription drug used to prevent or treat certain types of blood clots. Lovenox’s cost may depend on factors such as your dosage, whether you have health insurance, and how ...

Sanofi-Aventis said US sales of anti-thrombotic Lovenox were cut nearly in half by the launch of generic competition, an indication hospitals are showing little hesitation in using the copycat version ...

Sanofi-Aventis said today it lost a patent infringement case against two generic drug makers involving its top-selling product, the blockbuster bloodthinner Lovenox. Amphastar Pharmaceuticals and Teva ...

(Reuters) - The U.S. Food and Drug Administration issued a new warning on the use of the anticoagulant Lovenox in patients fitted with a spinal catheter because of the risk of spinal column bleeding ...

Sanofi’s big-selling blood thinner Lovenox has long faced generic competition in the U.S., but now rival generics makers are squashing long-running lawsuits over their own versions of the drug.

Sanofi-Aventis' anti-blood clot drug Lovenox reduced the risk of repeat heart attacks and deaths among people who suffered a major heart attack in a new study discussed at the annual scientific ...

Amphastar Pharmaceuticals finally has the FDA's blessing. After a protracted battle marked by lawsuits against the agency and conflicts of interest allegations, the ...

A California biotechnology company won Food and Drug Administration permission Monday to sell a generic version of the blockbuster blood thinner Lovenox, following a years-long battle that was ...

Uninsured people who paid out of pocket for the anticoagulant drug Lovenox may be eligible for a payment from a $120 million proposed settlement in a dispute between Nashville General Hospital and two ...

Well, we sort of figured this was coming. Sanofi-Aventis has gone to court here in Washington to prevent rival drugmaker Novartis from selling a generic version of the blockbuster blood-thinner ...

Emphasizing the tenet that antitrust laws are enacted to protect ­competition—and not competitors—the Third Circuit has rejected one competitor's claim that Sanofi-Aventis had an unfair advantage in ...